Illustrative image – not actual.Vivimed Labs has acquired Uquifa, manufacturer of active pharma ingredients (APIs) and intermediates with operations in Spain and Mexico.
The deal was valued at $55 million (approx Rs 286 crore). The acquisition will be funded by equity infusion of $20 million (approx Rs 104 crore), debt financing of $25 million (approx Rs 130 crore) and the balance of $10 million (approx Rs 52 crore) by way of deferred payment. Post acquisition, Uquifa will become the API division of Vivimed. The acquisition will strengthen Vivimed's current position in pharma APIs and intermediates while significantly improving the cost competitiveness of Uquifa.
Also See:
Vivimed Labs acquires Kolkata based Klar Sehen (4-October-11)
